


Midecamycin Acetate

酢酸ミデカマイシン



$C_{45}H_{71}NO_{17}$: 898.04
 (3*R*,4*S*,5*S*,6*R*,8*R*,9*R*,10*E*,12*E*,15*R*)-9-Acetoxy-5-[4-*O*-(3-*O*-acetyl-2,6-dideoxy-3-*C*-methyl-4-*O*-propionyl- α -*L*-ribo-hexopyranosyl)-3,6-dideoxy-3-dimethylamino- β -*D*-glucopyranosyloxy]-6-formylmethyl-4-methoxy-8-methyl-3-propionyloxyhexadeca-10,12-dien-15-olide
 [55881-07-7]

Midecamycin Acetate contains not less than 920 μ g (potency) per mg, calculated on the dried basis. The potency of Midecamycin Acetate is expressed as mass of midecamycin acetate ($C_{45}H_{71}NO_{17}$).

Description Midecamycin Acetate occurs as white, crystals or crystalline powder.

It is sparingly soluble in methanol, slightly soluble in ethanol (95), and practically insoluble in water.

Identification (1) Determine the absorption spectrum of a solution of Midecamycin Acetate in methanol (1 in 50,000) as directed under the Ultraviolet-visible Spectrophotometry, and compare the spectrum with the Reference Spectrum or the spectrum of a solution of Midecamycin Acetate Reference Standard prepared in the same manner as the sample solution: both spectra exhibit similar intensities of absorption at the same wavelength.

(2) Determine the infrared absorption spectrum of Midecamycin Acetate, previously dried, as directed in the potassium bromide disk method under the Infrared Spectrophotometry, and compare the spectrum with the Reference Spectrum or spectrum of dried Midecamycin Acetate Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

Purity Heavy metals—Proceed with 1.0 g of Midecamycin Acetate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

Loss on drying Not more than 2.0% (0.1 g, in vacuum not exceeding 0.67 kPa, 60°C, 3 hours).

Residue on ignition Not more than 0.20% (1 g).

Assay Perform the test according to the Cylinder-plate

method as directed under the Microbial Assay for Antibiotics according to the following conditions.

(1) Test organism—*Micrococcus luteus* ATCC 9341

(2) Culture medium—Use the medium i in 3) Medium for other organisms under (1) Agar media for seed and base layer.

(3) Standard solution—Weigh accurately an amount of Midecamycin Acetate Reference Standard, previously dried, equivalent to about 0.025 g (potency), and dissolve in methanol to make exactly 50 mL, and use this solution as the standard stock solution. Keep the standard stock solution at 5 – 15°C and use within 7 days. Take exactly a suitable amount of the standard stock solution before use, add 0.1 mol/L phosphate buffer solution, pH 4.5 to make solutions so that each mL contains 20 μ g (potency) and 5 μ g (potency), and use these solutions as the high concentration standard solution and the low concentration standard solution, respectively.

(4) Sample solution—Weigh accurately an amount of Midecamycin Acetate, previously dried, equivalent to about 0.025 g (potency), and dissolve in methanol to make exactly 50 mL. Take exactly a suitable amount of the solution, add 0.1 mol/L phosphate buffer solution, pH 4.5 to make solutions so that each mL contains 20 μ g (potency) and 5 μ g (potency), and use these solutions as the high concentration sample solution and the low concentration sample solution, respectively.

Containers and storage Containers—Tight containers.

Migrenin

ミグレニン

Migrenin is composed of 90 parts of antipyrine, 9 parts of caffeine, and 1 part of citric acid in mass.

Migrenin, when dried, contains not less than 87.0% and not more than 93.0% of antipyrine ($C_{11}H_{12}N_2O$: 188.23) and not less than 8.6% and not more than 9.5% of caffeine ($C_8H_{10}N_4O_2$: 194.19).

Description Migrenin occurs as a white powder or crystalline powder. It is odorless and has a bitter taste.

It is very soluble in water, freely soluble in ethanol (95) and in chloroform, and slightly soluble in diethyl ether.

The pH of a solution of Migrenin (1 in 10) is between 3.0 and 4.0.

It is affected by moisture and light.

Identification (1) To 5 mL of a solution of Migrenin (1 in 100) add 2 drops of sodium nitrite TS and 1 mL of dilute sulfuric acid: a deep green color develops.

(2) To 5 mL of a solution of Migrenin (1 in 50) add 1 drop of hydrochloric acid and 0.2 mL of formaldehyde solution, heat in a water bath for 30 minutes, add an excess of ammonia TS, and filter. Acidify the filtrate with hydrochloric acid, shake with 3 mL of chloroform, and separate the chloroform layer. Evaporate the chloroform solution on a water bath, add 10 drops of hydrogen peroxide TS and 1 drop of hydrochloric acid to the residue, and evaporate on a water bath to dryness: the residue shows a yellow-red color. Invert the residue over a vessel containing 3 drops of ammonia TS: a red-purple color develops, disappearing on the ad-

dition of 2 to 3 drops of sodium hydroxide TS.

(3) A solution of Migrenin (1 in 10) responds to the Qualitative Tests for citrate.

Melting point 104 – 110°C

Purity (1) Clarity and color of solution—Dissolve 1.0 g of Migrenin in 40 mL of water: the solution is clear and colorless to pale yellow.

(2) Heavy metals—Proceed with 1.0 g of Migrenin according to Method 1, and perform the test. Prepare the control solution with 2.0 mL of Standard Lead Solution (not more than 20 ppm).

Loss on drying Not more than 0.5% (1 g, in vacuum, silica gel, 4 hours).

Residue on ignition Not more than 0.10% (1 g).

Assay (1) Antipyrine—Weigh accurately about 0.25 g of Migrenin, previously dried in an iodine flask, dissolve in 25 mL of sodium acetate TS, add exactly 30 mL of 0.05 mol/L iodine VS, and allow to stand for 20 minutes with occasional shaking. Add 15 mL of chloroform to dissolve the precipitate so obtained, and titrate the excess iodine with 0.1 mol/L sodium thiosulfate VS (indicator: 3 mL of starch TS). Perform a blank determination.

$$\begin{aligned} \text{Each mL of 0.05 mol/L iodine VS} \\ = 9.411 \text{ mg of } C_{11}H_{12}N_2O \end{aligned}$$

(2) Caffeine—To about 1 g of Migrenin, previously dried and accurately weighed, add exactly 5 mL of the internal standard solution, dissolve in chloroform to make 10 mL, and use this solution as the sample solution. Separately, weigh accurately about 0.09 g of Caffeine Reference Standard, previously dried at 80°C for 4 hours, add exactly 5 mL of the internal standard solution, dissolve in chloroform to make 10 mL, and use this solution as the standard solution. Perform the test with 1 μ L each of the sample solution and the standard solution as directed under the Gas Chromatography according to the following conditions, and calculate the ratios, Q_T and Q_S , of the peak area of caffeine to that of the internal standard.

$$\begin{aligned} \text{Amount (mg) of caffeine (C}_8\text{H}_{10}\text{N}_4\text{O}_2\text{)} \\ = \text{amount (mg) of Caffeine Reference Standard} \\ \times \frac{Q_T}{Q_S} \end{aligned}$$

Internal standard solution—A solution of ethenzamide in chloroform (1 in 50).

Operating conditions—

Detector: A hydrogen flame-ionization detector.

Column: A glass column about 3 mm in inside diameter and about 2 m in length, packed with siliceous earth for gas chromatography (180 to 250 μ m in particle diameter) coated with 50% phenyl-methyl silicon polymer for gas chromatography at the ratio of 15%.

Column temperature: A constant temperature of about 210°C.

Carrier gas: Nitrogen

Flow rate: Adjust the flow rate so that the retention time of ethenzamide is about 4 minutes.

Selection of column: Dissolve 0.9 g of antipyrine and 0.09 g of caffeine in 10 mL of chloroform. Proceed with 1 μ L of this solution under the above operating conditions, and calculate the resolution. Use a column giving elution of caffeine and antipyrine in this order with the resolution be-


tween these peaks being not less than 1.5.

Containers and storage Containers—Tight containers.

Storage—Light-resistant.

Minocycline Hydrochloride

塩酸ミノサイクリン



$C_{23}H_{27}N_3O_7 \cdot HCl$: 493.94

(4*S*,4*aS*,5*aR*,12*aS*)-4,7-Bis(dimethylamino)-1,4,4*a*,5,5*a*,6,11,12*a*-octahydro-3,10,12,12*a*-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride [13614-98-7]

Minocycline Hydrochloride contains not less than 890 μ g (potency) per mg, calculated on the anhydrous basis. The potency of Minocycline Hydrochloride is expressed as mass (potency) of minocycline ($C_{23}H_{27}N_3O_7$: 457.48).

Description Minocycline Hydrochloride occurs as a yellow crystalline powder.

It is freely soluble in *N,N*-dimethylformamide, soluble in methanol, sparingly soluble in water, and slightly soluble in ethanol (95).

Identification (1) Determine the infrared absorption spectrum of Minocycline Hydrochloride as directed in the potassium chloride disk method under the Infrared Spectrophotometry, and compare the spectrum with the Reference Spectrum or the spectrum of Minocycline Hydrochloride Reference Standard: both spectra exhibit similar intensities of absorption at the same wave numbers.

(2) A solution of Minocycline Hydrochloride (1 in 100) responds to the Qualitative Test (2) for chloride.

Absorbance $E_{1\text{ cm}}^{1\%}$ (358 nm): 296 – 328 (8 mg, a solution of hydrochloric acid in methanol (19 in 20,000), 500 mL).

pH Dissolve 1.0 g of Minocycline Hydrochloride in 100 mL of water: the pH of the solution is between 3.5 and 4.5.

Purity (1) Heavy metals—Proceed with 0.5 g of Minocycline Hydrochloride according to Method 2, and perform the test. Prepare the control solution with 2.5 mL of Standard Lead Solution (not more than 50 ppm).

(2) Related substances—Dissolve 0.05 g of Minocycline Hydrochloride in 100 mL of the mobile phase, and use this solution as the sample solution. Perform the test immediately after the preparation of the sample solution with 20 μ L of the sample solution as directed under the Liquid Chromatography according to the following conditions, and measure each peak area by the automatic integration method. Calculate the amount of each peak area by the area percentage method: the amount of epiminocycline is not more than 1.2%, and the total area of the peaks other than